Daniel G. Anderson
Scientific Founder & Advisory Board MemberDr. Daniel G. Anderson, also known as Dan, Ph.D., is Scientific Founder & Advisory Board Member of CRISPR Therapeutics, Inc. Dr. Anderson is Founder and Director at Orna Therapeutics, Inc. He founded Olivo Laboratories, LLC in 2015. He is Founder of Soufflé Therapeutics, Inc. and serves as its Director. He serves as Scientific Advisory Committee Member at LS Polaris Innovation Fund. He is Co-Founder of Combined Therapeutics, Inc. and served as its Director until November 2021. Dr. Anderson is the Founder of VasoRx, Inc. and serves as its Member of Scientific Advisory Board. Dr. Anderson serves as Scientific Founder and Advisory Board Member at CRISPR Therapeutics AG. He Co-founded Living Proof, Inc in 2005. Dr. Anderson serves as Senior Scientific Advisor for the Living Proof discovery group as well as Senior Advisor on its intellectual property strategy. He serves as Research Associate and an Intramural Member of David H.Koch Institute for Integrative Cancer Research at MIT (Massachusetts Institute of Technology). Dr. Anderson pioneered the use of robotic methods for the development of smart biomaterials for drug delivery and tissue engineering. In particular, his work has enabled the rapid synthesis, formulation, analysis and biological testing of large libraries of biomaterials for use in medical devices, cell therapy and drug delivery. The advanced drug delivery systems developed in his laboratory have provided new methods for nanoparticulate and microparticulate drug delivery, non-viral gene therapy, siRNA delivery and vaccines. His lab’s research is centered on developing new materials for medicine. Dr. Anderson has expertise in Biodegradable, biocompatible engineered delivery materials and extracellular matrices. He serves as Member of Scientific Advisory Board at StemBioSys, Inc., Asterand Bioscience, Inc, Stemgent, Inc. and served as Member of Scientific Advisory Board at Fibrocell Science, Inc. He served as Director of Living Proof, Inc. He served as Member of the Scientific Advisory Board at Alnylam Pharmaceuticals, Inc. since June 2010. Dr. Anderson is the Sam Goldblith Associate Professor of Chemical Engineering and Medical Engineering and Science at MIT where his research is focused on developing new materials for medicine. He was appointed in Chemical Engineering, Harvard-MIT Division of Health Science and Technology. He is a faculty Member in the departments of Chemical Engineering, the Harvard-Massachusetts Institute of Technology (MIT) Division of Health Science Technology. His work has resulted in the publication of over 90 papers and pending patents. These patents have led to a number of licenses to pharmaceutical, chemical and biotechnology companies, with a number of products on the market or in clinical development. He has published more than 320 papers, patents and patent applications. He has co-founded seven companies and is actively working to translate his technology to seek the broadest positive human impact. Dr. Anderson received a BA in math and biology from the University of California at Santa Cruz. Dr. Anderson received his PhD in molecular genetics from the University of California at Davis.
Positions
- Company NameCRISPR Therapeutics AGStock CodeCRSPPositionScientific Founder & Advisory Board MemberColleagues
- SKSamarth KulkarniCEO & Chairman
- JRJames R. KasingerGeneral Counsel & Secretary
- RYRaju Yashaswi PrasadExecutive Officer
- NPNaimish PatelChief Medical Officer
- SFShaun FoyCo-Founder
- EMEmmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board Member
- CCCraig C. MelloScientific Founder & Advisory Board Member
- MPMatthew PorteusScientific Founder & Advisory Board Member
